TRESADERM DIN 00270512
Status: Cancelled Post Market
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: THIABENDAZOLE
Health Canada record
| Active ingredient(s) | THIABENDAZOLE 40 MG; NEOMYCIN (NEOMYCIN SULFATE) 3.2 MG; DEXAMETHASONE 1 MG |
|---|---|
| Dosage form | Solution |
| Route | Topical; Otic |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 31-Dec-1973 |
| Current status date | 21-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing THIABENDAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00140228 | MINTEZOL CHEWABLE TAB 500MG | MERCK SHARP & DOHME (UK) LTD. | Tablet | THIABENDAZOLE 500 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25648 | 2021-04-13 | Supplement to a New Drug Submission (SNDS) | ADDITION OF DRUG SUBSTANCE MANUFACTURER SITE - THIABENDAZOLE |
| 23515 | 2020-04-27 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 20326 | 2018-01-15 | Supplement to a New Drug Submission (SNDS) | CHANGE TO PRESCRIPTION STATUS.. LABELLING UPDATES |
| 6913 | 1997-12-03 | New Drug Submission (NDS) |
International API supply for THIABENDAZOLE
0 active FDA Drug Master Files.
Request a quote for TRESADERM